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012.08.00Abstract Aim of the work: To investigate whether serum leptin levels are elevated in patients with
rheumatoid arthritis (RA) and whether these levels correlate with disease activity.
Patients and methods: A case-control study was made on 37 patients with RA and 34 healthy
control subjects. The following values were assessed for each patient: erythrocyte sedimentation rate
(ESR), C reactive protein (CRP), rheumatoid factor (RF), swollen and tender joint counts, disease
activity score 28 (DAS28), health assessment questionnaire score (HAQ), visual analog scale (VAS)
of pain and serum leptin concentrations.
Results: Patients with RA had mild to moderate (DAS28 < 5.1) disease activity. The mean
serum leptin in patients with RA (12.15 ± 11.48 ng/mL) was signiﬁcantly higher (p< 0.001) than
controls (3.99 ± 1.84 ng/mL). Serum leptin levels were signiﬁcantly (p< 0.001) higher in female
RA patients than in female controls. A nonsigniﬁcant difference (p= 0.41) was found between
male patients with RA and male controls. Serum leptin levels were signiﬁcantly (p< 0.001) higher
in women than in men in both patients and controls. Serum leptin levels did not show correlationrtment of Rheumatology and
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186 A. Allam, A. Radwanwith age, disease duration, duration of morning stiffness, VAS, number of swollen and tender
joints, DAS28, HAQ, ESR or CRP in patients with RA. Serum leptin levels were correlated posi-
tively with BMI in RA patients. The BMI was signiﬁcantly higher (p< 0.001) in female than in
male patients with RA.
Conclusion: Although leptin levels were higher in RA patients, there was no correlation with dis-
ease activity parameters, therefore, leptin levels cannot be used to reﬂect disease activity.
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Rheumatoid arthritis (RA) is a chronic systemic autoimmune
inﬂammatory disease that is characterized by symmetrical
synovitis, progressive joint damage, pain, fatigue, and disabil-
ity. Although the exact cause of this disease is still unknown,
investigation of its pathogenesis has conﬁrmed the role of var-
ious pro-inﬂammatory cytokines, including tumor necrosis
factor-alpha (TNF-a), interleukin-1 (IL-1) and interleukin-6
(IL-6) [1–3]. Accordingly, inhibition of these cytokines has
become the new therapeutic strategy for RA. Recent studies
have demonstrated that cytokines secreted by adipocytes
(adipokines) have an important physiological role. Adipo-
kines, including resistin, leptin and adiponectin have been
demonstrated to inﬂuence eating behavior and the energy
balance, and have also been noted as new mediators of the
inﬂammatory process [4,5].
The increase in leptin production that occurs during infec-
tion and inﬂammation strongly suggests that leptin is a part of
the cytokine network which governs the inﬂammatory immune
response and the host defense mechanisms. Leptin plays an
important role in inﬂammatory processes involving T-cells
and has been reported to modulate T-helper cell activity in
the cellular immune response [6]. It is well known that leptin
has a dual role in inﬂammation. Leptin activates monocyte/
macrophage cells and potentiates production of the pro-
inﬂammatory cytokines, TNF-a, IL-6 and directs T-cell differ-
entiation to Th1 phenotype, expressing interferon c and IL-2
[7]. It also expresses certain anti-inﬂammatory substances by
releasing IL-1 receptor antagonist [8]. Several studies have
implicated leptin in the pathogenesis of autoimmune inﬂam-
matory conditions, such as experimental autoimmune enceph-
alomyelitis, type 1 diabetes, RA, and intestinal inﬂammation
[9–12]. The role of leptin in the modulation of immune re-
sponse and inﬂammation has become increasingly evident [6].
It has been suggested that leptin may inﬂuence the outcome
of RA [12].
The aim of this study was to assess the serum leptin levels
and their relationship with disease activity parameters in Egyp-
tian patients with RA.
2. Patients and methods
This case control study was conducted on RA patients attend-
ing the outpatient clinic of Rheumatology and Rehabilitation
Department, Sohag University Hospital, in the period between
May 2011 and September 2011. Thirty-seven patients (female/
male = 26/11) fulﬁlling the American College of Rheumatol-
ogy (ACR) criteria for a diagnosis of RA [13] with a mean
age of 45.95 ± 12.20 years were studied. Thirty-four controlsubjects (female/male = 21/13) with no inﬂammatory disease
were chosen from our outpatient clinic. The mean age of the
control subjects was 47.73 ± 12.84 years. Informed consent
was obtained from patients and controls participating in the
study. Age, sex, disease duration, body mass index (BMI)
(kg/m2) and swollen and tender joint counts of the RA patients
were recorded. Duration of morning stiffness, visual analog
scale of pain (VAS) [14], disease activity index 28 (DAS28)
[15], health assessment questionnaire (HAQ) [16,17], erythro-
cyte sedimentation rate (ESR) and C-reactive protein (CRP)
were used to assess disease activity. Disease activity index 28
(DAS28) is a validated index of RA disease activity. It consists
of four measures: 28 tender (TJC28) and swollen joint counts
(SJC28), ESR, and the patient’s general health (GH) measured
on a 100 mm visual analog scale. Patients were grouped
according to DAS28 scores as having high (DAS28 > 5.1) or
mild to moderate (DAS28 < 5.1) disease activity.
2.1. Laboratory investigations
Serum RF and CRP concentrations were determined by immu-
no-nephelometry methods on a Turbox nephelometer (Orion
Diagnostica, Finland). The concentrations were expressed as
IU/mL for RF and mg/l for CRP. RF concentration
P25 IU/mL and CRP concentrationP6 mg/l were considered
positive for RF and CRP respectively. The ESR was measured
by the Westergren method.
2.2. Determination of leptin levels
Venous blood samples were collected from every subject by
sterile veni-puncture on the same day of history taking and
clinical examination. Separated serum was kept frozen at
80 C till the time of estimation of serum leptin. Kits used
for determination were (DIA source Immuno-Assay S.A-Bel-
gium). The DIA-source leptin ELISA is a solid phase enzyme
ampliﬁed sensitivity immunoassay performed on microtiter-
plate. The assay uses monoclonal antibodies (MAbs) directed
against distinct epitopes of human leptin. Calibrators, quality
controls and samples react with the capture monoclonal anti-
body (MAb2) labeled with horseradish peroxidase (HRP).
After an incubation period allowing the formation of a sand-
wich: coated MAb1–human leptin–MAb2–HRP, the microtit-
erplate is washed to remove the unbound enzyme labeled
antibody. Bound enzyme-labeled antibody is measured
through a chromatographic reaction. Chromatographic solu-
tion (TMB ready for use) is added and incubated. The reaction
is stopped with the addition of stop solution and the microtit-
erplate is then read at the appropriate wavelength. The amount
of substrate turnover is determined colorimetrically by
Table 1 Demographic and clinical characteristics of rheumatoid arthritis (RA) patients and control.
Characteristics (mean ± SD) RA patients (37) Control (34) p value
Age (years) 45.95 ± 12.20 47.73 ± 12.84 0.532
Sex (F/M) 26/11 21/13 0.449
Disease duration (years) 3.57 ± 1.59 –
Rheumatoid factor (%) 28 (75.7%) –
Morning stiﬀness (min) 17.84 ± 8.04 –
VAS (0–10) 3.62 ± 1.40 –
Number of swollen joints 1.32 ± 1.16 –
Number of tender joints 2.89 ± 2.08 –
DAS28 score 3.59 ± 0.66 –
HAQ score 10.49 ± 4.15 –
ESR (mm/1st hr) 32.19 ± 12.30 –
CRP (mg/l) 10.65 ± 8.59 –
Body mass index (BMI) 25.81 ± 4.97 25.85 ± 1.62 0.963
Serum leptin (ng/mL) 12.15 ± 11.48 3.99 ± 1.84 0.001*
RF: rheumatoid factor; MS: morning stiffness; VAS: visual analog scale of pain; DAS28: disease activity for 28 joint indices score; HAQ: health
assessment questionnaire; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; BMI: body mass index.
* = Highly signiﬁcant.
Table 2 Serum leptin levels in patients with RA and in
controls according to the gender.
ng/mL RA patients (37) Control (34) p value
Females 16.08 ± 11.62 4.92 ± 1.60 <0.001*
Males 2.84 ± 0.99 2.48 ± 1.03 0.41
Total 12.15 ± 11.48 3.99 ± 1.84 <0.001*
* = High signiﬁcant correlation.
Figure 1 Serum leptin levels in patients with RA and in controls.
Table 3 Correlations between serum leptin levels and
patients’ characteristics.
Patient characteristics Serum leptin
r p
Age 0.08 0.64
Disease Duration 0.04 0.83
MS 0.31 0.06
VAS 0.18 0.28
No. of swollen joints 0.11 0.52
No. of tender joints 0.15 0.37
DAS28 0.02 0.89
HAQ 0.28 0.09
ESR 0.05 0.77
CRP 0.22 0.19
BMI 0.89 <0.001*
MS: morning stiffness; VAS: visual analog scale of pain; DAS28:
disease activity for 28 joint indices score; HAQ: health assessment
questionnaire; ESR: erythrocyte sedimentation rate; CRP: C-reac-
tive protein; BMI: body mass index.
* = High signiﬁcant correlation. Values were calculated using
Pearson’s correlation coefﬁcient.
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concentration. A calibration curve is plotted and leptin con-
centration in samples is determined by interpolation from the
calibration curve [18].
The results were analyzed by IBM-SPSS (version 19). Re-
sults were given as means and standard deviation. Student’s
t-test for continuous variables was used to examine the signif-
icance of differences between RA and control groups. p-value
less than 0.05 was regarded as signiﬁcant. The correlation be-
tween leptin levels and age, disease duration, duration of
morning stiffness, swollen and tender joint counts, VAS,
DAS28, HAQ, ESR, CRP and BMI was analyzed by Pearson
correlation analyses.
3. Results
Age, sex and BMI did not show statistically signiﬁcant differ-
ences between RA patients and control subjects (p> 0.05).
Patients with RA had mild to moderate (DAS28 < 5.1) dis-
ease activity. The demographic and clinical characteristics of
patients with RA and of control subjects are shown in Table 1.
The mean serum leptin in patients with RA
(12.15 ± 11.48 ng/mL) was signiﬁcantly higher (p< 0.001)
than controls (3.99 ± 1.84 ng/mL). The mean serum leptin
was signiﬁcantly (p< 0.001) higher in female RA patients
(16.08 ± 11.62 ng/mL) than in female controls
(4.92 ± 1.60 ng/mL). A nonsigniﬁcant difference (p 0.41) was
found between male patients with RA (2.84 ± 0.99 ng/mL)
and male controls (2.48 ± 1.03 ng/mL). The mean serum lep-
Table 4 Comparison of patients’ characteristics and parameters of disease activity between male and female RA patients.
Characteristics (mean ± SD) Males (11) Females (26) p value
Serum leptin (ng/mL) 2.84 ± 0.99 16.08 ± 11.62 <0.001*
Age (years) 46.36 ± 16.5 45.77 ± 10.25 0.89
Disease duration (years) 4.09 ± 1.45 3.35 ± 1.62 0.197
Rheumatoid factor positivity (no) 8 20 0.79
Morning stiﬀness (min) 20.91 ± 8 16.54 ± 7.84 0.13
VAS (0–10) 3.73 ± 1.1 3.58 ± 1.53 0.77
Number of swollen joints 1.45 ± 1.29 1.27 ± 1.12 0.66
Number of tender joints 3.36 ± 2.29 2.69 ± 1.99 0.38
DAS28 score 3.58 ± 0.49 3.59 ± 0.72 0.97
HAQ score 12.09 ± 4.39 9.81 ± 3.93 0.13
ESR (mm/1st hour) 28.27 ± 8.16 33.85 ± 13.48 0.21
CRP (mg/l) 12.18 ± 10.13 10 ± 7.98 0.49
Body mass index (BMI) 20.64 ± 1.36 28 ± 4.25 <0.001*
RF: rheumatoid factor; MS: morning stiffness; VAS: visual analog scale of pain; DAS28: disease activity for 28 joint indices score; HAQ: health
assessment questionnaire; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; BMI: body mass index.
* = High signiﬁcant correlation.
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in both patients and controls (Table 2 and Fig. 1).
Serum leptin levels did not show correlation with age, dis-
ease duration, duration of morning stiffness, VAS, number
of swollen and tender joints, DAS28, HAQ, ESR or CRP in
patients with RA. Serum leptin levels were correlated posi-
tively with BMI in RA patients (r= 0.89, p< 0.001)
(Table 3).
Patients’ characteristics and parameters of disease activity
did not show statistically signiﬁcant differences between male
and female patients with RA (p> 0.05). The body mass index
was signiﬁcantly higher (p< 0.001) in female than in male pa-
tients with RA (Table 4).4. Discussion
The role of leptin in human rheumatic diseases became the
subject of various studies [19]. Leptin likely plays a major role
in the pathogenesis of RA. In RA patients, it was reported that
fasting led to an improvement of different clinical and biologic
measures of disease activity, which was associated with a
marked decrease in serum leptin and a shift toward Th2 cyto-
kine production [20]. These features, resembling those previ-
ously depicted in ob/ob mice, suggest that leptin may also
inﬂuence the inﬂammatory mechanisms of arthritis in humans
through the induction of Th1 responses [6].
In the current study, the mean serum leptin in patients with
RA was signiﬁcantly higher than in controls. These results are
in consistent with other studies [12,19,21–26] and are contra-
dictory with others [27–31]. The reasons for this discrepancy
between our study and these studies may be related to the ef-
fects of medications used for treatment or to the differences
in body mass indices of patients with RA. Rho et al. [32] sug-
gested that the higher concentrations of leptin in patients with
RA than controls can be attributed to differences in inﬂamma-
tion rather than BMI. Simons et al. [33] described that TNFa
and IL-1b stimulate leptin production by human preadipo-
cytes. Nonetheless, it is not obvious whether the increase of
plasma leptin in RA is just an effect of weight change or it is
rather a cause or a consequence of pathology in RA [34].In this study the mean serum leptin in female patients with
RA was signiﬁcantly higher than in female controls while a
nonsigniﬁcant difference was found between male patients
with RA and male controls. Yoshino et al. [35] reported that
serum leptin levels were signiﬁcantly higher in male and female
RA patients than in the corresponding controls. Nishiya et al.
[36] found no difference in serum leptin between male and fe-
male patients with RA and the corresponding controls.
In our study the mean serum leptin was signiﬁcantly higher
in females than males in both patients and controls and this re-
sult is in agreement with other studies [19,37] that reported
that concentrations of leptin were signiﬁcantly higher in wo-
men than in men. There are studies reporting that gonadal ste-
roids have an effect on circulating leptin levels. Testosterone
inhibited the expression of this hormone, whereas it was in-
creased by ovarian sex steroids [38] and this fact may explain
higher plasma leptin levels in women than in men, even after
adjustment for BMI [34,39]. Also, leptin is one of the hor-
mones favoring the greater predisposition of women to auto-
immune diseases [40].
In the current study, there were no correlations between
serum leptin levels and age, disease duration, duration of
morning stiffness, VAS, swollen and tender joint counts,
DAS28, HAQ, CRP and ESR. Our results were similar to
those reported in other studies [27,19,29,31,41]. In contrast,
other studies [23–25,37,42] found that serum leptin level was
signiﬁcantly correlated with disease duration and parameters
of RA activity. Serum leptin levels were higher, but did not
correlate with disease activity parameters in systemic lupus
erythematosus (SLE) in a study performed by Garcia-Gonz-
alez et al. [43]. Based on these ﬁndings in a review article, Pal-
mer and Gabay [44] stated that leptin cannot be used to
evaluate disease activity in RA and SLE patients.
In our study, serum leptin levels showed positive correlation
withBMI in patientswithRA [19,22,25,27,30,34,38] andwomen
had signiﬁcantly higher levels thanmen, as seen in previous stud-
ies [45,46]. In one study, this sex difference was reported not to
be related to sex hormones or fat distribution, but possibly to
differences in the hypothalamic regulation of leptin production
or in adipose tissue biologic characteristics [46]. Targon´ska-
Stepniak et al. [37] reported that the leptin concentrations corre-
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hand, this positive correlation between serum leptin levels and
BMI in patients with RA, was not found in another study [24]
which suggested that regulation of leptinemia is complex and
leptin levels cannot be used to assess RA activity.
In conclusion, even though serum leptin levels were found
to be signiﬁcantly higher in RA patients than in control sub-
jects in this study, there was no correlation between serum lep-
tin levels and clinical and laboratory parameters of disease
activity. However serum leptin levels were positively correlated
with BMI in patients with RA. In RA, circulating leptin levels
do not seem to reﬂect disease activity.
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